Abstract: TH-PO1279
Sodium Thiosulfate Attenuates Coronary Artery Calcification and Uremic Pruritus: A Randomized Crossover Trial
Session Information
- Late-Breaking Research Posters
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Sun, Chensi, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
- Hao, Jiao Jiao, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
- Lin, Hongli, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
Background
Sodium thiosulfate (STS) may attenuate coronary artery calcification (CAC) and uremic pruritus (UP) in maintenance hemodialysis (MHD) patients, but biomarkers of response remain limited. Extracellular vesicle (EV)-derived miR-122b-3p has been implicated in vascular smooth muscle cell calcification. We investigated whether serum EV-derived miR-122b-3p was associated with STS-related changes in CAC and UP.
Methods
In this open-label, randomized crossover trial, MHD patients were assigned 1:1 to STS or usual care for 8 weeks, followed by crossover after a 2-week washout. Primary outcomes were changes in CAC score (CACs) and pruritus severity by Duo's Pruritus Score. Exploratory outcomes included changes in serum EV-derived miR-122b-3p and its associations with CACs and UP.
Results
Of 93 screened patients, 61 had both CAC and UP, and 37 completed both treatment periods. Compared with control, STS attenuated CAC progression [CACs change: 11.6 (−55.7 to 89.1) vs 59.8 (16.4 to 210.2), P = 0.014] and reduced pruritus severity [−4 (−6 to −2) vs 2 (2 to 2), P < 0.001]. CAC progression was less frequent during STS [20/37 (54.1%) vs 31/37 (83.8%), P = 0.011]. Baseline EV-derived miR-122b-3p correlated with CACs (r = 0.934, P < 0.001). STS decreased miR-122b-3p levels, and miR-122b-3p changes correlated with changes in CACs (r = 0.745, P < 0.001) and pruritus severity (r = 0.427, P = 0.009).
Conclusion
STS attenuated CAC progression and UP. Serum EV-derived miR-122b-3p may serve as a noninvasive biomarker of CAC burden and STS response.
Funding
- Commercial Support – Shanghai SPH New ASIA Pharma